Innate Pharma S.A. (NASDAQ:IPHA – Get Rating) – SVB Leerink dropped their FY2026 EPS estimates for Innate Pharma in a report released on Tuesday, May 10th. SVB Leerink analyst D. Graybosch now forecasts that the company will earn $0.58 per share for the year, down from their prior forecast of $0.75.
Other research analysts also recently issued research reports about the company. Zacks Investment Research downgraded Innate Pharma from a “hold” rating to a “sell” rating in a research note on Tuesday, May 3rd. HC Wainwright reaffirmed a “buy” rating and set a $11.50 price target on shares of Innate Pharma in a research note on Friday, March 25th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $9.90.
A number of hedge funds have recently made changes to their positions in IPHA. Morgan Stanley raised its stake in Innate Pharma by 993.8% in the 1st quarter. Morgan Stanley now owns 56,110 shares of the company’s stock valued at $242,000 after purchasing an additional 50,980 shares during the last quarter. Affinity Asset Advisors LLC acquired a new position in Innate Pharma in the 3rd quarter valued at about $771,000. Balyasny Asset Management LLC acquired a new position in Innate Pharma in the 3rd quarter valued at about $1,157,000. Pura Vida Investments LLC acquired a new position in Innate Pharma in the 3rd quarter valued at about $509,000. Finally, Cubist Systematic Strategies LLC acquired a new position in Innate Pharma in the 3rd quarter valued at about $124,000. 1.74% of the stock is owned by hedge funds and other institutional investors.
Innate Pharma Company Profile (Get Rating)
Innate Pharma SA, a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase II clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; and IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway.
- Get a free copy of the StockNews.com research report on Innate Pharma (IPHA)
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
Receive News & Ratings for Innate Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innate Pharma and related companies with MarketBeat.com's FREE daily email newsletter.